Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928966 | 0.87 | HPGD (0.57) | HRH3HPGDKDM4EALDH1A1RAPGEF3 | |
| SCHEMBL25391576 | 0.79 | HDAC1 (0.61) | HDAC1HDAC8HDAC6HRH3HRH4 | |
| SCHEMBL3275430 | 0.78 | HDAC1 (0.69) | HDAC1HDAC8HDAC6HRH3HRH4 | |
| SCHEMBL30737599 | 0.78 | HPGD (0.61) | HPGDKDM4EALDH1A1 | |
| SCHEMBL395103 | 0.77 | GSK3B (0.48) | HPGDKDM4EALDH1A1 | |
| SCHEMBL28784579 | 0.76 | HRH3 (0.69) | HDAC1HDAC8HDAC6HRH3HRH4 | |
| SCHEMBL2787677 | 0.76 | HDAC1 (0.67) | HDAC1HDAC8HDAC6HRH3HRH4 | |
| SCHEMBL3275253 | 0.76 | HRH3 (0.69) | HDAC1HDAC8HDAC6HRH3HRH4 | |
| SCHEMBL30737498 | 0.76 | HPGD (0.65) | HPGDKDM4EALDH1A1 | |
| SCHEMBL15448626 | 0.76 | HDAC1 (0.52) | HDAC1HDAC8HDAC6HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | HDAC1 136/4885HDAC8 246/4885HDAC6 205/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | HDAC1 136/4885HDAC8 246/4885HDAC6 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.